Bulk Manufacturer of Controlled Substances Application: Cedarburg Pharmaceuticals, 48562-48563 [2020-17434]
Download as PDF
<![CDATA[
48562
Federal Register / Vol. 85, No. 155 / Tuesday, August 11, 2020 / Notices
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
By order of the Commission.
Issued: August 5, 2020.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2020–17465 Filed 8–10–20; 8:45 am]
BILLING CODE 7020–02–P
JUDICIAL CONFERENCE OF THE
UNITED STATES
Advisory Committees on Appellate,
Bankruptcy, Civil, and Criminal Rules;
Hearings of the Judicial Conference
Judicial Conference of the
United States, Advisory Committees on
the Federal Rules of Appellate,
Bankruptcy, Civil, and Criminal
Procedure.
ACTION: Notice of proposed amendments
and open hearings.
AGENCY:
The Advisory Committees on
Appellate, Bankruptcy, Civil, and
Criminal Rules have proposed
amendments to the following rules:
Appellate Rule: 25
Bankruptcy Rules: Restyled Rules Parts
I and II; Rules 1007, 1020, 2009, 2012,
2015, 3002, 3010, 3011, 3014, 3016,
3017.1, 3017.2 (new), 3018, 3019,
5005, 7004, and 8023; and Official
Forms 101, 122B, 201, 309E–1, 309E–
2, 309F–1, 309F–2, 314, 315, and
425A
Civil Rules: Rule 12 and Supplemental
Rules for Social Security Review
Actions Under 42 U.S.C. 405(g)
Criminal Rule: 16
The text of the proposed rules and the
accompanying committee notes, along
with the related forms, will be posted by
August 14, 2020, on the Judiciary’s
website at: https://www.uscourts.gov/
rules-policies/proposed-amendmentspublished-public-comment.
All written comments and suggestions
with respect to the proposed
amendments may be submitted on or
after the opening of the period for
public comment on August 14, 2020,
but no later than February 16, 2021.
SUMMARY:
VerDate Sep<11>2014
17:02 Aug 10, 2020
Jkt 250001
Written comments must be submitted
electronically, following the
instructions provided on the website.
All comments submitted will be posted
on the website and available to the
public.
Remote public hearings via video or
telephone conference are scheduled on
the proposed amendments as follows:
• Appellate Rules on October 19,
2020 and January 4, 2021;
• Bankruptcy Rules on January 7,
2021 and January 29, 2021;
• Civil Rules on November 10, 2020
and January 22, 2021; and
• Criminal Rules on November 4,
2020 and January 25, 2021.
Those wishing to testify must contact
the Secretary of the Committee on Rules
of Practice and Procedure by email at:
RulesCommittee_Secretary@
ao.uscourts.gov, at least 30 days before
the hearing.
FOR FURTHER INFORMATION CONTACT:
Rebecca A. Womeldorf, Secretary,
Committee on Rules of Practice and
Procedure of the Judicial Conference of
the United States, Thurgood Marshall
Federal Judiciary Building, One
Columbus Circle NE, Suite 7–300,
Washington, DC 20544, Telephone (202)
502–1820, RulesCommittee_Secretary@
ao.uscourts.gov.
Authority: 28 U.S.C. 2073.
Dated: August 5, 2020.
Shelly L. Cox,
Rules Committee Staff.
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on July 15, 2020, Cambrex
High Point, Inc., 4180 Mendenhall Oaks
Parkway, High Point, North Carolina
27265–8017, applied to be registered as
an importer of the following basic
class(es) of a controlled substance:
ADDRESSES:
Controlled substance
Poppy Straw Concentrate.
The company plans to import the
listed controlled substance for research
purposes.
[FR Doc. 2020–17436 Filed 8–10–20; 8:45 am]
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–700]
Importer of Controlled Substances
Application: Cambrex High Point, Inc.
Drug Enforcement Administration
[Docket No. DEA–698]
Bulk Manufacturer of Controlled
Substances Application: Cedarburg
Pharmaceuticals
AGENCY:
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Cambrex High Point, Inc.
applied to be registered as an importer
of the following basic class(es) of a
controlled substance: Poppy Straw
Concentrate.
SUMMARY:
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before September 10, 2020. Such
persons may also file a written request
for a hearing on the application on or
before September 10, 2020.
DATES:
Fmt 4703
II
BILLING CODE 4410–09–P
BILLING CODE 2210–55–P
Frm 00063
9670
Schedule
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020–17458 Filed 8–10–20; 8:45 am]
PO 00000
Drug
code
Sfmt 4703
Cedarburg Pharmaceuticals
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substances:
Tetrahydrocannabinol,
Methylphenidate, Nabilone, 4-AnilinoN-phenethyl-4-piperidine (ANPP), and
Fentanyl.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before October 13, 2020.
E:\FR\FM\11AUN1.SGM
11AUN1
48563
Federal Register / Vol. 85, No. 155 / Tuesday, August 11, 2020 / Notices
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on June 24, 2020,
Cedarburg Pharmaceuticals, 870 Badger
Circle, Grafton, Wisconsin 53024–0000,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substances:
ADDRESSES:
Controlled substance
Tetrahydrocannabinols ..
Methylphenidate ............
Nabilone ........................
4-Anilino-N-phenethyl-4piperidine (ANPP).
Fentanyl .........................
Drug
code
Schedule
7370
1724
7379
8333
I
II
II
II
9801
II
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for a hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on July 10, 2020, Epic
Pharma, LLC, 227–15 North Conduit
Avenue, Laurelton, New York 11413
applied to be registered as an importer
of the following basic class(es) of a
controlled substance:
Controlled substance
The company plans to manufacture
bulk active pharmaceutical ingredients
(API) for distribution to its customers. In
reference to drug code 7370
(Tetrahydrocannabinols) the company
plans to bulk manufacture as synthetic.
No other activity for this drug code is
authorized for this registration.
Methadone ....................
Drug
code
9250
Schedule
The company plans to import the
listed controlled substance for research
and analytical purposes.
William T. McDermott,
Assistant Administrator.
DEPARTMENT OF JUSTICE
[Docket No. DEA–701]
Bulk Manufacturer of Controlled
Substances Application: Purisys, LLC
[Docket No. DEA–695]
Importer of Controlled Substances
Application: Epic Pharma, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
VerDate Sep<11>2014
17:02 Aug 10, 2020
Jkt 250001
Purisys, LLC applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substances: Lysergic acid diethylamide
and Pentobarbital.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before October 13, 2020.
ADDRESS: Written comments should be
sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUMMARY:
Epic Pharma, LLC applied to
be registered as an importer of the
following basic class(es) of a controlled
substance: Methadone.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before September 10, 2020. Such
persons may also file a written request
for a hearing on the application on or
before September 10, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
SUMMARY:
In
accordance with 21 CFR 1301.33(a), this
is notice that on July 15, 2020, Purisys,
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00064
Fmt 4703
7315
I
2270
II
The company plans to manufacture
the above-listed controlled substances
as analytical reference standards and
clinical trial material for distribution to
its customers. No other activities for
these drug codes are authorized for this
registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020–17438 Filed 8–10–20; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–697]
Importer of Controlled Substances
Application: GE Healthcare
Sfmt 4703
GE Healthcare applied to be
registered as an importer of the
following basic class(es) of a controlled
substance: Cocaine.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before September 10, 2020. Such
persons may also file a written request
for a hearing on the application on or
before September 10, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUMMARY:
Drug Enforcement Administration
Drug Enforcement Administration
Schedule
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
[FR Doc. 2020–17434 Filed 8–10–20; 8:45 am]
DEPARTMENT OF JUSTICE
Lysergic acid
diethylamide.
Pentobarbital ................
Drug
code
AGENCY:
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
Controlled substance
II
[FR Doc. 2020–17432 Filed 8–10–20; 8:45 am]
William T. McDermott,
Assistant Administrator.
LLC, 1550 Olympic Drive, Athens,
Georgia 30601–1602, applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substances:
E:\FR\FM\11AUN1.SGM
11AUN1
]]>Agencies
[Federal Register Volume 85, Number 155 (Tuesday, August 11, 2020)]
[Notices]
[Pages 48562-48563]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-17434]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-698]
Bulk Manufacturer of Controlled Substances Application: Cedarburg
Pharmaceuticals
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Cedarburg Pharmaceuticals applied to be registered as a bulk
manufacturer of the following basic class(es) of controlled substances:
Tetrahydrocannabinol, Methylphenidate, Nabilone, 4-Anilino-N-phenethyl-
4-piperidine (ANPP), and Fentanyl.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before October 13,
2020.
[[Page 48563]]
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on June 24, 2020, Cedarburg Pharmaceuticals, 870 Badger
Circle, Grafton, Wisconsin 53024-0000, applied to be registered as a
bulk manufacturer of the following basic class(es) of controlled
substances:
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols.................. 7370 I
Methylphenidate........................ 1724 II
Nabilone............................... 7379 II
4-Anilino-N-phenethyl-4-piperidine 8333 II
(ANPP).
Fentanyl............................... 9801 II
------------------------------------------------------------------------
The company plans to manufacture bulk active pharmaceutical
ingredients (API) for distribution to its customers. In reference to
drug code 7370 (Tetrahydrocannabinols) the company plans to bulk
manufacture as synthetic. No other activity for this drug code is
authorized for this registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-17434 Filed 8-10-20; 8:45 am]
BILLING CODE 4410-09-P
